Prevention of chemotherapy-related bone loss with doxorubicin-loaded solid lipid nanoparticles

<b>Aim:</b> Breast cancer and its metastases involve high mortality even with advances in chemotherapy. Solid lipid nanoparticles provide a platform for drug delivery, reducing side effects and treatment-induced bone loss. A solid nanoparticle containing doxorubicin was evaluated for its ability to prevent bone loss in a pre-clinical breast cancer model. <b>Methods:</b> We investigated the effects of SLNDox in an aggressive metastatic stage IV breast cancer model, which has some important features that are interesting for bone loss investigation. This study evaluates bone loss prevention potential from solid lipid nanoparticles containing doxorubicin breast cancer treatment, an evaluation of the attenuation of morphological changes in bone tissue caused by the treatment and the disease and an assessment of bone loss imaging using computed tomography and electron microscopy. <b>Results:</b> Chemotherapy-induced bone loss was also observed in tumor-free animals; a solid lipid nanoparticle containing doxorubicin prevented damage to the growth plate and to compact and cancellous bones in the femur of tumor-bearing and healthy animals. <b>Conclusion:</b> The association of solid lipid nanoparticles with chemotherapeutic drugs with proven efficacy promotes the prevention of serious consequences of chemotherapy, reducing tumor progression, increasing quality of life and improving prognosis and survival. The treatment of breast cancer leads to an imbalance in bone metabolism, promoting the reabsorption of the mineral portion of the tissue. The use of doxorubicin is widespread in the clinic, but it intensifies bone loss, reducing survival. The use of solid lipid nanoparticles containing doxorubicin is promising as a treatment capable of mitigating adverse effects. SLNDox prevented bone loss in mice, preventing the reduction of mineralization and changes in the architecture of long bones. When the treatment is administered to animals with tumors, SLNDox also prevents damage to the growth plate, in addition to calcium loss and reduction in cancellous bone volume. In addition to the benefits of using nanostructures to treat neoplasms, the potential for preventing long-term damage has been observed with the prevention of bone loss through:○ Reducing the concentration of doxorubicin in the kidneys and heart.○ Delaying tumor progression and the emergence of lung metastases.○ Preventing the destruction of cancellous bone.○ Preventing demineralization of bone tissue. Reducing the concentration of doxorubicin in the kidneys and heart. Delaying tumor progression and the emergence of lung metastases. Preventing the destruction of cancellous bone. Preventing demineralization of bone tissue.